Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Journal article

BACKGROUND: Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol. METHODS: 2838 patients aged 40-75 years in 132 ce...

Expand abstract

Authors: Colhoun, H; Betteridge, D; Durrington, P; Hitman, G; Neil, H

• Journal: Lancet
• Volume: 364
• Issue: 9435
• Pages: 685-696
• Publication date: 2004-01-01
• DOI: 10.1016/s0140-6736(04)16895-5
• EISSN: 1474-547X
• ISSN: 0140-6736
• Language: English
• Keywords: Humans; Pyrroles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; CARDS investigators; Middle Aged; Adult; Risk Factors; Male; Aged; Heptanoic Acids; Cholesterol, LDL; Coronary Disease; Cardiovascular Diseases; Double-Blind Method; Anticholesteremic Agents; Stroke; Female; Diabetes Mellitus, Type 2